IA
DNLI icon

IFP Advisors’s Denali Therapeutics DNLI Stock Holding History

IFP Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Buy
503
+494
+5,489% +$10.2K ﹤0.01% 3236
2026
Q1 		$173 Hold
9
– – ﹤0.01% 4649
2025
Q4 		$149 Hold
9
– – ﹤0.01% 4524
2025
Q3 		$131 Buy
+9
New +$129 ﹤0.01% 4493
2025
Q2 		– Hold
0
– – – 2756
2025
Q1 		– Sell
-1
Closed -$20 – 4393
2024
Q4 		$20 Buy
+1
New +$26 ﹤0.01% 4454
2023
Q1 		– Sell
-15
Closed -$1K – 3632
2022
Q4 		$1K Buy
+15
New +$446 ﹤0.01% 4322
2021
Q2 		– Sell
-20
Closed -$1.24K – 3102
2021
Q1 		$1K Sell
20
-4
-17% -$268 ﹤0.01% 2809
2020
Q4 		$2K Buy
24
+9
+60% +$544 ﹤0.01% 2596
2020
Q3 		$1K Buy
+15
New +$452 ﹤0.01% 2619

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFP Advisors's DNLI Position: Q2 2026 in Review

IFP Advisors increased its Denali Therapeutics (DNLI) stake by 5,489% in Q2 2026, buying an estimated $10.2K and bringing the position to 503 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3236.

IFP Advisors first reported a position in DNLI in Q3 2020 and has held it in 9 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • IFP Advisors held 503 shares of Denali Therapeutics worth $12.9K as of Q2 2026.
  • IFP Advisors bought 494 Denali Therapeutics shares in Q2 2026, an estimated $10.2K.
  • Denali Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3236 holding.
  • IFP Advisors first reported a position in Denali Therapeutics in Q3 2020 and has held it in 9 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.